“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

21 June 2019
Pharma

Visiongain has launched a new pharma report Global (IBD) Drug Market Report: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis, Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

IBD incidence and prevalence is evolving worldwide and is now anticipated to be an emerging global disease. The inflammatory bowel diseases (IBD) drug market will continue to be driven by rising disease incidence and more-effective non-invasive diagnosis.

The lead analyst of the report commented "Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis. Economic development of newly industrialized countries is expected to intensify, and several developing countries will make the transition to the status of newly industrialized countries. The magnitude of the growth of IBD in newly industrialized countries will depend on several factors, including exposure to relevant environmental risk factors, urbanization of the population, access to health care, the speed of adoption of medical technologies such as colonoscopy, and natural population growth. Advances in electronic surveillance of diseases will also enhance reporting of IBD from many regions that currently lack data."

Leading companies featured in the report include AbbVie, Allergan, Biogen, Celgene Corporation, Gilead Sciences, Janssen, Novartis, Pfizer, Roche, Takeda, UCB Pharma S.A. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever